The RSV vaccine Abrysvo was highly effective against hospital and ED encounters in a large cohort of older adults with comorbidities and immunocompromising conditions.

The respiratory syncytial virus (RSV) vaccine (Abrysvo) was linked with fewer hospitalizations and emergency department (ED) ...

Starting Oct. 28, the rest of the general public are recommended to also get vaccinated, says region's health unit ...

Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or ...

A multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the RSV -- ...

What is this silent virus that endangers Filipino Seniors with comorbidities? Respiratory Syncytial Virus (RSV) is not just another cold or flu—it is potentially life- threatening for ...

Merck’s (NYSE:MRK) monoclonal antibody clesrovimab, designed as a prophylactic against respiratory syncytial virus (RSV), has ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval ...

Merck has reported positive Phase IIb/III trial data for clesrovimab, its investigational RSV antibody, showing a 60.4% ...

More than a dozen Toronto schools have signed up for “spit kits,” a Hospital for Sick Children initiative that allows ...

By analyzing respiratory samples such as VTM and BAL, the expanded infexn - NGS test offers clinicians a more streamlined ...

A mother’s worst nightmare is watching her child fall gravely ill, feeling helpless as the condition becomes worse. When ...